AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17013594 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg Gd‐DTPA
Number of subjects: 60
Study 17013594 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mmol/kg Gd‐DTPA
Number of subjects: 60
Study 17013594 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mmol/kg Gd‐DTPA
Number of subjects: 60
Study 17013594 — intervention group
Group type: EXPERIMENTAL
Intervention: Image masking (subtraction of baseline images)
Number of subjects: 60
Study 17013594 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg, 0.2 mmol/kg, 0.3 mmol/kg Gd‐DTPA
Number of subjects: 60
Study 17013594 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing contrast agent dosage
Number of subjects: 60
Study 15653005 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hormone replacement therapy with 0.3mg of conjugated equine estrogens (CE) and 2.5 mg MPA (CE + MPA)
Number of subjects: 40
Study 15653005 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hormone replacement therapy with 0.3mg of conjugated equine estrogens (CE) and 100 mg natural micronized progesterone (CE + P)
Number of subjects: 40
Study 15653005 — intervention group
Group type: COMPARATOR
Intervention: Control group (calcium-vitamin)
Number of subjects: 40
Study 15653005 — intervention group
Group type: EXPERIMENTAL
Intervention: CE + MPA and CE + P
Number of subjects: 40
Study 15653005 — intervention group
Group type: EXPERIMENTAL
Intervention: CE + P
Number of subjects: 40
Study 12505240 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9790357 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir (500 mg twice daily)
Number of subjects: 20
Study 9790357 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir (400 mg 3 times daily)
Number of subjects: 20
Study 7542336 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine (0, 0.5, 2, 8, 16 and 32 mg)
Number of subjects: 9
Study 7542336 — intervention group
Group type: EXPERIMENTAL
Intervention: p.o. methadone (3.75, 15 and 60 mg)
Number of subjects: 9
Study 7542336 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of buprenorphine
Number of subjects: 9
Study 7542336 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of methadone
Number of subjects: 9
Study 2221770 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.6 ml/kg, 0.25% = 1.5 mg/kg) injected intradermally into the wound during general anaesthesia
Number of subjects: 20
Study 2221770 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia only
Number of subjects: 20
Study 6110433 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium 1 mg kg‐1
Number of subjects: 0
Study 6110433 — intervention group
Group type: COMPARATOR
Intervention: Control (no suxamethonium)
Number of subjects: 0
Study 30855743 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% fluorouracil cream
Number of subjects: 624
Study 30855743 — intervention group
Group type: COMPARATOR
Intervention: 5% imiquimod cream
Number of subjects: 624
Study 30855743 — intervention group
Group type: COMPARATOR
Intervention: methyl aminolevulinate photodynamic therapy (MAL‐PDT)
Number of subjects: 624
Study 30855743 — intervention group
Group type: COMPARATOR
Intervention: 0.015% ingenol mebutate gel
Number of subjects: 624
Study 28209654 — intervention group
Group type: EXPERIMENTAL
Intervention: CGM-only (n = 149)
Number of subjects: 226
Study 28209654 — intervention group
Group type: COMPARATOR
Intervention: CGM+BGM (n = 77)
Number of subjects: 226
Study 26111150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (usual treatment group)
Number of subjects: 336
Study 24453236 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental intervention (specific details not provided)
Number of subjects: 0
Study 24453236 — intervention group
Group type: EXPERIMENTAL
Intervention: Dog-leg design
Number of subjects: 0
Study 24453236 — intervention group
Group type: COMPARATOR
Intervention: Parallel groups design
Number of subjects: 0
Study 19040615 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg of proinsulin peptide (C19-A3) administered intradermally in three equal doses at 0, 1, and 2 months
Number of subjects: 36
Study 19040615 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 microg of proinsulin peptide (C19-A3) administered intradermally in three equal doses at 0, 1, and 2 months
Number of subjects: 36
Study 19040615 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg of proinsulin peptide (C19-A3)
Number of subjects: 36
Study 19040615 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 36
Study 17325084 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline treatment
Number of subjects: 61
Study 17325084 — intervention group
Group type: COMPARATOR
Intervention: No doxycycline treatment (Control)
Number of subjects: 61
Study 16518446 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape intervention
Number of subjects: 136
Study 16518446 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 136
Study 14656271 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-paclitaxel regimen
Number of subjects: 2
Study 14656271 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin-cyclophosphamide regimen
Number of subjects: 2
Study 10368990 — intervention group
Group type: EXPERIMENTAL
Intervention: Testicular biopsies showing complete or nearly complete tubular hyalinization
Number of subjects: 21
Study 10368990 — intervention group
Group type: EXPERIMENTAL
Intervention: Testicular biopsies from five patients
Number of subjects: 21
Study 9381939 — intervention group
Group type: EXPERIMENTAL
Intervention: sulphurous thermal water
Number of subjects: 50
Study 9381939 — intervention group
Group type: COMPARATOR
Intervention: placebo saline solution
Number of subjects: 50
Study 2060150 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (1-29)NH2 10 micrograms/kg/h
Number of subjects: 10
Study 2060150 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine 60 mg
Number of subjects: 10
Study 2060150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6340575 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 19
Study 6340575 — intervention group
Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 19
Study 31814452 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg intravenous bolus of tranexamic acid (TXA) in high-risk patients (Hb < 13.0 g/dL)
Number of subjects: 256
Study 31814452 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg intravenous bolus of tranexamic acid (TXA) in low-risk patients (Hb ≥ 13.0 g/dL)
Number of subjects: 256
Study 31814452 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TXA) in high-risk patients
Number of subjects: 256
Study 31814452 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TXA) in low-risk patients
Number of subjects: 256
Study 31814452 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA in both groups
Number of subjects: 256
Study 31814452 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA in high-risk patients
Number of subjects: 256
Study 31814452 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA in low-risk patients
Number of subjects: 256
Study 28581335 — intervention group
Group type: COMPARATOR
Intervention: Daily diary writing
Number of subjects: 119
Study 28581335 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured biographical writing
Number of subjects: 119
Study 28581335 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstructured biographical writing
Number of subjects: 119
Study 26991138 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 μg/kg anti-D globulin
Number of subjects: 60
Study 26991138 — intervention group
Group type: COMPARATOR
Intervention: 1 g/kg IV immune globulin (IVIG)
Number of subjects: 60
Study 25792578 — intervention group
Group type: EXPERIMENTAL
Intervention: Pocket-size ultrasound examinations performed by medical residents
Number of subjects: 199
Study 23765409 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier generic switches within the index ATC code
Number of subjects: 2476
Study 23765409 — intervention group
Group type: EXPERIMENTAL
Intervention: Having had more than five earlier switches within other ATC codes
Number of subjects: 2476
Study 23765409 — intervention group
Group type: EXPERIMENTAL
Intervention: Having negative views on generic medicines
Number of subjects: 2476
Study 23765409 — intervention group
Group type: COMPARATOR
Intervention: Generic substitution
Number of subjects: 2476
Study 19874340 — intervention group
Group type: EXPERIMENTAL
Intervention: Flashlamp-pumped dye laser (FPDL) with 0.45 ms pulse duration tuned to 585 nm
Number of subjects: 24
Study 19874340 — intervention group
Group type: COMPARATOR
Intervention: Long-pulse-duration dye laser (LPDL) with 1.5 or 3.0 ms pulse duration tuned to 595 nm
Number of subjects: 24
Study 19874340 — intervention group
Group type: EXPERIMENTAL
Intervention: Both lasers
Number of subjects: 24
Study 17965444 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram (DIS) 200 mg per day
Number of subjects: 243
Study 17965444 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX) 50 mg per day
Number of subjects: 243
Study 17965444 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate (ACA) 1998 mg per day
Number of subjects: 243
Study 17965444 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 243
Study 15904629 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 173
Study 12904486 — intervention group
Group type: EXPERIMENTAL
Intervention: +30 degrees rotation during center-out-and-back reaching movements
Number of subjects: 0
Study 12904486 — intervention group
Group type: EXPERIMENTAL
Intervention: -30 degrees rotation during different tasks (continuous tracking, figure-eight drawing)
Number of subjects: 0
Study 12904486 — intervention group
Group type: COMPARATOR
Intervention: Control group (never experienced the opposite rotation)
Number of subjects: 0
Study 10561144 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral sodium phosphate (Na(2)HPO(4))
Number of subjects: 28
Study 10561144 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (NaCl)
Number of subjects: 28
Study 8991468 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2 mg/kg induction, 15-20 mg/kg x h maintenance with 30% O2 in air)
Number of subjects: 130
Study 8991468 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2 mg/kg induction, 10-15 mg/kg x h maintenance with N2O)
Number of subjects: 130
Study 8991468 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone (5 mg/kg induction, 0.8-1.5 Vol% isoflurane maintenance with N2O in 30% O2)
Number of subjects: 130
Study 8991468 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (0.8-1.5 Vol% with N2O in 30% O2)
Number of subjects: 130
Study 1652604 — intervention group
Group type: EXPERIMENTAL
Intervention: SK&F 104353 (963 +/- 43.7 micrograms)
Number of subjects: 6
Study 1652604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 6139671 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (100 mg three times a day)
Number of subjects: 12
Study 6139671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30623907 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry variables including forced vital capacity, forced expiratory volume in 1 second, ratio between the two, peak expiratory flow rate, forced expiratory flow between 25% and 75% expired volume
Number of subjects: 751
Study 28947757 — intervention group
Group type: EXPERIMENTAL
Intervention: RD + H2O2 photolysis
Number of subjects: 53
Study 28947757 — intervention group
Group type: EXPERIMENTAL
Intervention: RD followed by minocycline chloride gel
Number of subjects: 53
Study 28947757 — intervention group
Group type: COMPARATOR
Intervention: RD alone
Number of subjects: 53
Study 25873142 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Activation and Education (PAE) including text messaging, print and web-based tutorials over 12 months
Number of subjects: 0
Study 25873142 — intervention group
Group type: EXPERIMENTAL
Intervention: PAE plus physician activation (PAE + MD)
Number of subjects: 0
Study 25873142 — intervention group
Group type: EXPERIMENTAL
Intervention: PAE plus physician activation, plus teledermoscopy (PAE + MD + TD)
Number of subjects: 0
Study 23538523 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP‐IPV‐Hep B‐PRP‐T vaccine coadministered with MMR+V
Number of subjects: 567
Study 23538523 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR+V coadministered with DTaP‐IPV‐Hep B‐PRP‐T vaccine
Number of subjects: 567
Study 23538523 — intervention group
Group type: COMPARATOR
Intervention: Control DTwP‐Hib, hepatitis B and oral poliovirus vaccines
Number of subjects: 567
Study 21418883 — intervention group
Group type: EXPERIMENTAL
Intervention: Yousilin R
Number of subjects: 211
Study 21418883 — intervention group
Group type: COMPARATOR
Intervention: Novolin R
Number of subjects: 211
Study 20035636 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengths and Difficulties Questionnaire with Impact Supplement (SDQ)
Number of subjects: 2066
Study 20035636 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Symptom Checklist (PSC)
Number of subjects: 2066
Study 20035636 — intervention group
Group type: EXPERIMENTAL
Intervention: PSYBOBA
Number of subjects: 2066
Study 16963137 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine 3mg
Number of subjects: 20
Study 16963137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 14551368 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate concentration 32 mmol/l (modality A)
Number of subjects: 26
Study 14551368 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate concentration 26 mmol/l (modality B)
Number of subjects: 26
Study 10841169 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg/day
Number of subjects: 290
Study 10841169 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 2.5 mg/day
Number of subjects: 290
Study 10841169 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined risedronate treatment groups
Number of subjects: 290
Study 10841169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 9093797 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofenac (100 mg twice daily)
Number of subjects: 240
Study 9093797 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam (20 mg once daily and placebo once daily)
Number of subjects: 240
Study 9093797 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofenac
Number of subjects: 240
Study 9093797 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam
Number of subjects: 240
Study 1301246 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 40
Study 1301246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2863596 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis (intracoronary streptokinase up to 250,000 U, with some receiving intravenous streptokinase 500,000 U)
Number of subjects: 533
Study 2863596 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 533
Study 2863596 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 533
Study 30060984 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus low-exposure (LE)
Number of subjects: 35
Study 30060984 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus high-exposure (HE)
Number of subjects: 35
Study 30060984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 30060984 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (both LE and HE)
Number of subjects: 35
Study 28318290 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting stress (personal distress)
Number of subjects: 164
Study 28318290 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting stress (child rearing stress)
Number of subjects: 164
Study 28318290 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative affectivity
Number of subjects: 164
Study 26429652 — intervention group
Group type: EXPERIMENTAL
Intervention: Brazil nuts (15 to 30 g, 3 days/week)
Number of subjects: 129
Study 26429652 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Brazil nuts)
Number of subjects: 129
Study 26429652 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 129
Study 26429652 — intervention group
Group type: EXPERIMENTAL
Intervention: Macapá group
Number of subjects: 129
Study 24170749 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein (HP) meal
Number of subjects: 33
Study 24170749 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat (HF) meal
Number of subjects: 33
Study 24170749 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat/high-protein (HF/HP) meal
Number of subjects: 33
Study 24170749 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein (HP) meals
Number of subjects: 33
Study 21207228 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (100 mg/m² by intravenous infusion over 3 hours)
Number of subjects: 34
Study 21207228 — intervention group
Group type: COMPARATOR
Intervention: Protease inhibitors (not specified)
Number of subjects: 34
Study 19960293 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbst appliance
Number of subjects: 42
Study 19960293 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Mandibular Advancer
Number of subjects: 42
Study 18257349 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus ear point tapping and pressing therapy
Number of subjects: 50
Study 18257349 — intervention group
Group type: COMPARATOR
Intervention: Sibutramine (10 mg orally once daily)
Number of subjects: 50
Study 15051195 — intervention group
Group type: EXPERIMENTAL
Intervention: ATT sequence (argon laser trabeculoplasty - trabeculectomy - trabeculectomy)
Number of subjects: 581
Study 15051195 — intervention group
Group type: EXPERIMENTAL
Intervention: TAT sequence (trabeculectomy - argon laser trabeculoplasty - trabeculectomy)
Number of subjects: 581
Study 15051195 — intervention group
Group type: EXPERIMENTAL
Intervention: ATT sequence
Number of subjects: 581
Study 15051195 — intervention group
Group type: EXPERIMENTAL
Intervention: TAT sequence
Number of subjects: 581
Study 15051195 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 581
Study 11715639 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate (PC)
Number of subjects: 25
Study 11715639 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium-sodium citrate (PSC)
Number of subjects: 25
Study 11715639 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-sodium citrate (CSC)
Number of subjects: 25
Study 11715639 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary citrate elevation (urine A)
Number of subjects: 25
Study 11715639 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary pH elevation (urine B)
Number of subjects: 25
Study 11783269 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM) combined with hypoglycemic agent
Number of subjects: 52
Study 11783269 — intervention group
Group type: COMPARATOR
Intervention: Hypoglycemic agent alone
Number of subjects: 52
Study 7797783 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine cleaning measures including daily cleaning of smooth floors, weekly laundering of sheets, and monthly cleaning of soft toys; use of synthetic mattress covers.
Number of subjects: 30
Study 2194867 — intervention group
Group type: EXPERIMENTAL
Intervention: Amox-CA (Augmentin)
Number of subjects: 101
Study 2194867 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin-metronidazole +/- aminoglycoside
Number of subjects: 101
Study 384920 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical percussion physiotherapy
Number of subjects: 14
Study 384920 — intervention group
Group type: COMPARATOR
Intervention: Manual percussion physiotherapy
Number of subjects: 14
Study 30903613 — intervention group
Group type: EXPERIMENTAL
Intervention: AE + B + Ad (acid etching + Biosilicate + total-etch adhesive)
Number of subjects: 30
Study 30903613 — intervention group
Group type: EXPERIMENTAL
Intervention: B (Biosilicate)
Number of subjects: 30
Study 30903613 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 30
Study 26425932 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted LP
Number of subjects: 111
Study 26425932 — intervention group
Group type: COMPARATOR
Intervention: Conventional LP
Number of subjects: 111
Study 25460095 — intervention group
Group type: EXPERIMENTAL
Intervention: Risky driving motor vehicle commercial condition
Number of subjects: 0
Study 25460095 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-risky driving motor vehicle commercial condition
Number of subjects: 0
Study 25460095 — intervention group
Group type: COMPARATOR
Intervention: Control non-motor vehicle commercial condition
Number of subjects: 0
Study 23649578 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode Laser (DL)
Number of subjects: 54
Study 23649578 — intervention group
Group type: COMPARATOR
Intervention: 0.4% Stannous Fluoride Gel
Number of subjects: 54
Study 23649578 — intervention group
Group type: COMPARATOR
Intervention: 5% Potassium Nitrate Gel
Number of subjects: 54
Study 21735693 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin therapy (1700 mg daily for 6 months)
Number of subjects: 30
Study 20104753 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG 400 mg/(kg x d) for 5 days or IVIG 1 g/(kg x d) for 2 days
Number of subjects: 48
Study 20104753 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir (GCV) 5-10 mg/(kg x d) for 5 days
Number of subjects: 48
Study 20104753 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 48
Study 16916184 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 0
Study 16916184 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 0
Study 16916184 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0
Study 16916184 — intervention group
Group type: COMPARATOR
Intervention: Intravenous anaesthesia
Number of subjects: 0
Study 16916184 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled anaesthetics
Number of subjects: 0
Study 12625640 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous NMES
Number of subjects: 0